Biosimilars Expansion And EU Approvals Will Unlock Global Markets

Shared on01 May 25
Fair value Decreased 14%

Shared on23 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25
Fair value Decreased 0.45%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25
Fair value Increased 12%

AnalystConsensusTarget has decreased revenue growth from 8.8% to 7.3% and increased future PE multiple from 21.8x to 24.5x.

Shared on02 Apr 25
Fair value Decreased 8.88%

Shared on26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25
Fair value Increased 8.62%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on12 Mar 25
Fair value Decreased 3.05%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.